• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于全球数据网络的 COVID-19 对多发性骨髓瘤患者的影响。

Impact of COVID-19 in patients with multiple myeloma based on a global data network.

机构信息

Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain.

Biomedical Informatics Group, Universidad Politécnica de Madrid, Madrid, Spain.

出版信息

Blood Cancer J. 2021 Dec 10;11(12):198. doi: 10.1038/s41408-021-00588-z.

DOI:10.1038/s41408-021-00588-z
PMID:34893583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8661359/
Abstract

The COVID-19 pandemic has represented a major cause of morbidity/mortality worldwide, overstressing health systems. Multiple myeloma (MM) patients show an increased risk for infections and they are expected to be particularly vulnerable to SARS-CoV-2 infection. Here we have obtained a comprehensive picture of the impact of COVID-19 in MM patients on a local and a global scale using a federated data research network (TriNetX) that provided access to Electronic Medical Records (EMR) from Health Care Organizations (HCO) all over the world. Through propensity score matched analyses we found that the number of new diagnoses of MM was reduced in 2020 compared to 2019 (RR 0.86, 95%CI 0.76-0.96) and the survival of newly diagnosed MM cases decreased similarly (HR 0.61, 0.38-0.81). MM patients showed higher risk of SARS-CoV-2 infection (RR 2.09, 1.58-2.76) and a higher excess mortality in 2020 (difference in excess mortality 9%, 4.4-13.2) than non-MM patients. By interrogating large EMR datasets from HCO in Europe and globally, we confirmed that MM patients have been more severely impacted by COVID-19 pandemic than non-MM patients. This study highlights the necessity of extending preventive measures worlwide to protect vulnerable patients from SARS-CoV-2 infection by promoting social distancing and an intensive vaccination strategies.

摘要

COVID-19 大流行是全球发病和死亡的主要原因,使卫生系统不堪重负。多发性骨髓瘤(MM)患者感染风险增加,预计特别容易感染 SARS-CoV-2。在这里,我们使用一个联合数据研究网络(TriNetX),从世界各地的医疗保健组织(HCO)获取电子病历(EMR),从本地和全球范围全面了解 COVID-19 对 MM 患者的影响。通过倾向评分匹配分析,我们发现与 2019 年相比,2020 年 MM 的新诊断数量减少(RR 0.86,95%CI 0.76-0.96),新诊断 MM 病例的生存率也相似下降(HR 0.61,0.38-0.81)。MM 患者感染 SARS-CoV-2 的风险更高(RR 2.09,1.58-2.76),2020 年的超额死亡率也更高(超额死亡率差异 9%,4.4-13.2)。通过调查来自欧洲和全球 HCO 的大型 EMR 数据集,我们证实 MM 患者比非 MM 患者受到 COVID-19 大流行的严重影响。这项研究强调,有必要在全球范围内扩大预防措施,通过促进社交距离和强化疫苗接种策略,保护弱势群体免受 SARS-CoV-2 感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/d78fa1b70fdf/41408_2021_588_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/aa73c34b005c/41408_2021_588_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/bfcc1ac4a861/41408_2021_588_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/d78fa1b70fdf/41408_2021_588_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/aa73c34b005c/41408_2021_588_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/bfcc1ac4a861/41408_2021_588_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c323/8664903/d78fa1b70fdf/41408_2021_588_Fig3_HTML.jpg

相似文献

1
Impact of COVID-19 in patients with multiple myeloma based on a global data network.基于全球数据网络的 COVID-19 对多发性骨髓瘤患者的影响。
Blood Cancer J. 2021 Dec 10;11(12):198. doi: 10.1038/s41408-021-00588-z.
2
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.SARS-CoV-2 感染后神经和精神风险轨迹:包括 1284437 名患者的 2 年回顾性队列研究分析。
Lancet Psychiatry. 2022 Oct;9(10):815-827. doi: 10.1016/S2215-0366(22)00260-7. Epub 2022 Aug 17.
3
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.204 个国家和地区及 811 个次国家级行政单位 1950 年至 2021 年的全球年龄、性别特异性死亡率、预期寿命和人口估计,以及 COVID-19 大流行的影响:2021 年全球疾病负担研究的综合人口分析。
Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11.
4
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
5
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma.基于反事实解释的处理后平均处理效应(SATT)分析表明,BMT 和 SARS-CoV-2 疫苗接种是与多发性骨髓瘤患者 COVID-19 严重程度和生存相关的保护性风险因素。
Blood Cancer J. 2023 Dec 7;13(1):180. doi: 10.1038/s41408-023-00901-y.
6
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.236379 例 COVID-19 幸存者的 6 个月神经和精神结局:使用电子健康记录的回顾性队列研究。
Lancet Psychiatry. 2021 May;8(5):416-427. doi: 10.1016/S2215-0366(21)00084-5. Epub 2021 Apr 6.
7
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球 204 个国家和地区及 811 个亚级行政区 1990 年至 2021 年 288 种死因及预期寿命的归因分析:全球疾病负担研究 2021 系统分析。
Lancet. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2. Epub 2024 Apr 3.
8
Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.利用世界死亡率数据集追踪 COVID-19 大流行期间各国的超额死亡率。
Elife. 2021 Jun 30;10:e69336. doi: 10.7554/eLife.69336.
9
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.三等级中心治疗 COVID-19 合并多发性骨髓瘤患者的经验:教训与未来方向。
J Hematol Oncol. 2020 Jul 14;13(1):94. doi: 10.1186/s13045-020-00934-x.
10
Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study.意义未明单克隆丙种球蛋白血症患者感染 COVID-19 的风险和严重程度:一项为期 3 年的倾向评分匹配队列研究。
Clin Lymphoma Myeloma Leuk. 2023 Aug;23(8):626-632. doi: 10.1016/j.clml.2023.04.010. Epub 2023 Apr 28.

引用本文的文献

1
Time trends in multiple myeloma incidence and mortality across the BRICS from 1992 to 2021 and projection to 2046.1992年至2021年金砖国家多发性骨髓瘤发病率和死亡率的时间趋势及到2046年的预测。
BMC Public Health. 2025 May 13;25(1):1765. doi: 10.1186/s12889-025-22688-2.
2
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.健康的社会决定因素对多发性骨髓瘤治疗模式及结局的影响
Future Oncol. 2025 Jun;21(13):1663-1673. doi: 10.1080/14796694.2025.2498878. Epub 2025 May 12.
3
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.

本文引用的文献

1
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.接种疫苗的血液系统恶性肿瘤成年患者中的 COVID-19:来自 EPICOVIDEHA 的初步结果。
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
2
Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients.造血干细胞移植受者针对严重急性呼吸综合征冠状病毒2的体液和细胞疫苗接种反应
Vaccines (Basel). 2021 Sep 25;9(10):1075. doi: 10.3390/vaccines9101075.
3
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
多发性骨髓瘤患者接种第三剂严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗后的体液和细胞免疫反应随访
Front Immunol. 2025 Feb 18;16:1532947. doi: 10.3389/fimmu.2025.1532947. eCollection 2025.
4
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.在1/2期MajesTEC-1研究中,COVID-19对复发/难治性多发性骨髓瘤患者使用替西帕单抗治疗结局的影响。
Blood Cancer J. 2024 Oct 21;14(1):186. doi: 10.1038/s41408-024-01160-1.
5
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.管理和治疗血液系统恶性肿瘤患者的 COVID-19:叙述性综述和专家观点。
Clin Exp Med. 2024 Jun 4;24(1):119. doi: 10.1007/s10238-024-01381-5.
6
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real-world study.来那度胺维持治疗在多发性骨髓瘤中的全国性实施:一项回顾性真实世界研究。
EJHaem. 2024 Mar 27;5(2):316-324. doi: 10.1002/jha2.881. eCollection 2024 Apr.
7
COVID-19 Vaccine Uptake in Patients with Multiple Myeloma and AL Amyloidosis: A Cross-Sectional Observational Study from India.印度多发性骨髓瘤和AL淀粉样变性患者的新冠疫苗接种情况:一项横断面观察性研究
Indian J Hematol Blood Transfus. 2024 Jan;40(1):30-35. doi: 10.1007/s12288-023-01680-z. Epub 2023 Jul 22.
8
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.免疫抑制对抗 SARS-CoV-2 mRNA 疫苗接种多发性骨髓瘤患者的负面影响。
Int J Hematol. 2024 Jan;119(1):50-61. doi: 10.1007/s12185-023-03680-1. Epub 2023 Dec 12.
9
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma.基于反事实解释的处理后平均处理效应(SATT)分析表明,BMT 和 SARS-CoV-2 疫苗接种是与多发性骨髓瘤患者 COVID-19 严重程度和生存相关的保护性风险因素。
Blood Cancer J. 2023 Dec 7;13(1):180. doi: 10.1038/s41408-023-00901-y.
10
A population-based study on incidence trends of myeloma in the United States over 2000-2020.一项基于人群的研究,调查了 2000 年至 2020 年期间美国多发性骨髓瘤的发病趋势。
Sci Rep. 2023 Nov 24;13(1):20705. doi: 10.1038/s41598-023-47906-y.
西班牙血液学和输血学会关于肿瘤血液病患者 SARS-CoV-2 疫苗接种的专家共识意见。
Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20.
4
Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain.癌症与 2019 年冠状病毒病诊断、住院和死亡的风险:一项包括西班牙加泰罗尼亚 4618377 名成年人的基于人群的多州队列研究。
Int J Cancer. 2022 Mar 1;150(5):782-794. doi: 10.1002/ijc.33846. Epub 2021 Nov 3.
5
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者:欧洲血液学协会调查(EPICOVIDEHA)。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
6
COVID-19 infection in patients with acute leukemia; Istanbul experience.急性白血病患者的新型冠状病毒肺炎感染:伊斯坦布尔的经验
Am J Blood Res. 2021 Aug 15;11(4):427-437. eCollection 2021.
7
Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.成人急性髓系白血病患者中由新型冠状病毒肺炎导致的死亡率:一项针对巴西血液学家的调查
Ann Hematol. 2022 Apr;101(4):923-925. doi: 10.1007/s00277-021-04659-w. Epub 2021 Sep 17.
8
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.COVID-19 与癌症:基于登记数据的大流行应对措施综述。
JAMA Oncol. 2021 Dec 1;7(12):1882-1890. doi: 10.1001/jamaoncol.2021.4083.
9
Impact of the COVID-19 pandemic on lung cancer diagnosis and treatment.2019年冠状病毒病大流行对肺癌诊断和治疗的影响。
Med Clin (Barc). 2022 Feb 11;158(3):138-139. doi: 10.1016/j.medcli.2021.07.004. Epub 2021 Jul 26.
10
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.慢性髓性白血病患者中 SARS-CoV-2 感染的血清流行率与一般人群相似。
Cancer Med. 2021 Sep;10(18):6310-6316. doi: 10.1002/cam4.4179. Epub 2021 Aug 31.